This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Celgene: Revlimid Cancer Risk Knocks Stock

Update: A third clinical trial of long-term Revlimid treatment in multiple myeloma patients yielded yet more evidence of an increase in secondary cancers. More details below, with updated stock price information.

SUMMIT, N.J. ( TheStreet) -- Does Celgene's (CELG - Get Report) best-selling cancer drug Revlimid cause cancer?

Celgene's Revlimid is one of the most successful blood cancer drugs on the market, with 2010 sales expected to reach $2.45 billion. But a small amount of new data presented this weekend --not conclusive by any means -- suggests that multiple myeloma patients treated with Revlimid for extended periods of time are being diagnosed with secondary cancers at a rate higher than patients not treated with Revlimid.

In other words, Revlimid, while keeping multiple myeloma in remission for years, may also be putting these same patients at higher risk for developing other forms of cancer.

Celgene shares closed Monday down $4.95, or 8%, to $55.64 on worries that the "secondary malignancy risk" attributable to Revlimid could pinch the drug's long-term growth prospects. Central to the Celgene growth story is more and longer use of Revlimid to maintain remissions in patients with multiple myeloma.

Celgene shares dropped another 3% to $52 in Monday's after-hours session after more worrisome Revlimid secondary cancer data were revealed.

Updated data presented over the weekend at the American Society of Hematology annual meeting from a study of Revlimid long-term maintenance therapy in multiple myeloma reported 15 cases of secondary malignancies in Revlimid patients compared to six cases of secondary cancer in placebo patients. Another 4 cases of secondary cancer were reported in patients enrolled in the study but who had not yet been randomized to receive either Revlimid or placebo.

The number of secondary cancer cases is very small and might have been explained away as a simple statistical anomaly except for the fact that the worrisome trend showed up twice again Monday during presentations of data from two other trials investigating long-term use of Revlimid.

Across three separate studies totaling about 1,060 patients, long-term Revlimid treatment was associated with 32 secondary cancers, or 5.9%, compared to 9 secondary cancers, or 1.7%, in patients treated with a placebo, according to pooled data compiled by ISI Group biotech analyst Mark Schoenebaum.

In an email to clients earlier Monday, before the data from the third Revlimid study was presented, Schoenebaum said the new cancer data will "very likely create a new overhang on Celgene shares" although he also notes that the studies demonstrating a definitive benefit favoring maintenance use of Revlimid and that the imbalance in secondary cancers reported might be due to the simple fact that Revlimid patients are being followed for adverse events much longer than placebo patients.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CELG $108.05 1.80%
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%
TSLA $247.54 -1.60%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs